<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449524</url>
  </required_header>
  <id_info>
    <org_study_id>CXA-10-301</org_study_id>
    <nct_id>NCT03449524</nct_id>
  </id_info>
  <brief_title>PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)</brief_title>
  <acronym>PAH</acronym>
  <official_title>Phase 2 Multicenter, Double-Blind, Placebo Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Complexa, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philips Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiovascular Clinical Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MicroConstants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovative Analytics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Complexa, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy&#xD;
      and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to&#xD;
      80 years of age with PAH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy&#xD;
      and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to&#xD;
      80 years of age with PAH.&#xD;
&#xD;
      The study will be performed in approximately 50 study centers across the United States of&#xD;
      America and Europe. The recruitment period is anticipated to be approximately 24 months.&#xD;
      Approximately 115 subjects will be enrolled to ensure at least 96 subjects complete the&#xD;
      study.&#xD;
&#xD;
      Study participation for each subject will last approximately 8 months. The study will consist&#xD;
      of a screening period (within 30 days prior to dosing), 180 days (approximately 6 months)&#xD;
      treatment period and approximately 14 days follow-up period after the end of treatment visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    LOE&#xD;
  </why_stopped>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">August 5, 2020</completion_date>
  <primary_completion_date type="Actual">August 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>CXA-10</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right Ventricular Ejection Fraction (RVEF)</measure>
    <time_frame>6 months</time_frame>
    <description>• To determine the efficacy of oral doses of CXA-10 on stable background therapy administered for 6 months in subjects with PAH assessed by right ventricular ejection fraction (RVEF) as measured by Cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Vascular Resistance (PVR)</measure>
    <time_frame>6 months</time_frame>
    <description>• To determine the efficacy of oral doses of CXA-10 on stable background therapy administered for 6 months in subjects with PAH assessed by pulmonary vascular resistance (PVR) as measured by right heart catheterization (RHC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Distance (6MWD)</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the efficacy of oral doses of CXA-10 on stable background therapy administered for 6 months in subjects with PAH assessed by 6 minute walk distance (6MWD)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>PAH</condition>
  <arm_group>
    <arm_group_label>75mg CXA-10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily dosing of 75mg CXA-10 in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150mg CXA-10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily dosing of 150mg CXA-10 in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily dosing in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75mg CXA-10</intervention_name>
    <description>CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)</description>
    <arm_group_label>75mg CXA-10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150mg CXA-10</intervention_name>
    <description>CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)</description>
    <arm_group_label>150mg CXA-10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females between 18 to 80 years of age inclusive at Screening&#xD;
&#xD;
          -  Weight ≥40 kg&#xD;
&#xD;
          -  Must have a diagnosis of WHO Group 1 PH&#xD;
&#xD;
          -  Have a World Health Organization (WHO) Classification of Functional Status Class II or&#xD;
             III of patients with PH&#xD;
&#xD;
          -  Must meet hemodynamic criteria by means of a right heart catheterization&#xD;
&#xD;
          -  Meet pulmonary function test parameters&#xD;
&#xD;
          -  A 6 MWD test of ≥125m and ≤550m at the visit&#xD;
&#xD;
          -  Subjects must have a resting arterial oxygen saturation (SaO2) ≥90%, with or without&#xD;
             supplemental oxygen, as measured by pulse oximetry at Screening&#xD;
&#xD;
          -  Subjects enrolled in a prescribed exercise program for pulmonary rehabilitation must&#xD;
             be in a stable program for 3 months prior to Screening (Visit 1) and must agree to&#xD;
             maintain their current level of rehabilitation throughout the study. If subjects are&#xD;
             not enrolled in a prescribed exercise training program for pulmonary rehabilitation,&#xD;
             they cannot enroll during the Screening/Baseline Period or throughout the study&#xD;
&#xD;
          -  If receiving simvastatin-containing products: dose should not exceed 20 mg/day&#xD;
&#xD;
          -  Subjects must be receiving no more than three of the following previously approved PAH&#xD;
             therapies: phosphodiesterase type 5 (PDE-5) inhibitors, endothelin receptor antagonist&#xD;
             (ERA), soluble guanylate cyclase (sGC) stimulator, prostanoids, prostacyclin receptor&#xD;
             agonists and must be on stable doses (≥3 months) at Screening (Visit 1)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for CMRI imaging&#xD;
&#xD;
          -  WHO Groups 2, 3, 4 and 5 Pulmonary Hypertension&#xD;
&#xD;
          -  Unrepaired congenital heart defects and significant congenital heart defects (i.e.,&#xD;
             atrial septal defects, ventricular septal defects, and patent ductus arteriosus)&#xD;
             repaired less than 1 year prior to Screening (Visit 1) (Group 1 classification of&#xD;
             Pulmonary Hypertension)&#xD;
&#xD;
          -  QTcF &gt; 500 msec&#xD;
&#xD;
          -  Acute myocardial infarction or acute coronary syndrome within the last 90 days&#xD;
&#xD;
          -  Cerebrovascular accident/transient ischemic attack (CVA/TIA) within the last 90 days&#xD;
&#xD;
          -  Hospitalization for left heart failure within the last 90 days&#xD;
&#xD;
          -  Clinically significant aortic or mitral valve disease defined as greater than mild&#xD;
             regurgitation or mild stenosis; pericardial constriction; restrictive or constrictive&#xD;
             cardiomyopathy; left ventricular dysfunction (LVEF &lt; 50%); left ventricular outflow&#xD;
             obstruction; symptomatic coronary artery disease; autonomic hypotension; or fluid&#xD;
             depletion&#xD;
&#xD;
          -  Chronic atrial fibrillation and life-threatening cardiac arrhythmias&#xD;
&#xD;
          -  Personal or family history of congenital prolonged QTc syndrome or sudden or sudden&#xD;
             unexpected death due to a cardiac reason&#xD;
&#xD;
          -  Clinically significant anemia&#xD;
&#xD;
          -  Severe hepatic impairment or active chronic hepatitis&#xD;
&#xD;
          -  Receiving intravenous inotropes within 2 weeks prior to Screening&#xD;
&#xD;
          -  History of angina pectoris or other condition that was treated with long or short&#xD;
             acting nitrates &lt;12 weeks of Screening&#xD;
&#xD;
          -  Received prednisone doses &gt;15mg/day or changes in immunosuppressive medications &lt; 12&#xD;
             weeks prior to Screening (Visit 1)&#xD;
&#xD;
          -  Recent (within 1 year) history of abusing alcohol or illicit drugs.&#xD;
&#xD;
          -  History of any primary malignancy, with no evidence of disease for at least 5 years&#xD;
&#xD;
          -  Treatment with any investigational drug or device within 30 days or 5 half-lives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theo Danoff, MD</last_name>
    <role>Study Director</role>
    <affiliation>Complexa, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-2202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital (Medstar)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdventHealth</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153-3328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesotta</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University and Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10279</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christ Hospital-Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INTEGRIS Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State M.S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbuilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia School of Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Medical Campus</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedert Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton</name>
      <address>
        <city>London</city>
        <zip>SW3 6HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>PAH</keyword>
  <keyword>Connective Tissue Disease-Associated</keyword>
  <keyword>6 Minute Walk Test</keyword>
  <keyword>6 Minute Walk Distance</keyword>
  <keyword>Pulmonary Vascular Resistance</keyword>
  <keyword>Cardiac MRI</keyword>
  <keyword>Right Ventricular Function</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Familial Primary Pulmonary Hypertension</keyword>
  <keyword>Connective Tissue Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Hypertension, Pulmonary</keyword>
  <keyword>Lung Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>CXA-10</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

